Phase 3 Trial of Apraglutide in Short Bowel Syndrome and Intestinal Failure: Sub-Analyses by Baseline Demographics and Disease Characteristics
Background: Apraglutide, a long-acting glucagon-like peptide-2 analog administered subcutaneously once-weekly, stimulates intestinal adaptation and reduces PS requirements, as shown in the pivotal STARS trial. Here we present subgroup analyses of the STARS primary endpoint by baseline demographic and SBS disease-specific characteristics.
Authors
- Chang Ming (ORCID: https://orcid.org/0000-0002-2817-3865)
- Mena Boules (ORCID: https://orcid.org/0000-0002-5962-9271)
- Susanna Y. Huh (ORCID: https://orcid.org/0009-0007-0114-2456)
- Francisca Joly (ORCID: https://orcid.org/0000-0002-9341-7133)
- Kelly A. Tappenden (ORCID: https://orcid.org/0000-0001-8412-6476)
- Donald F. Kirby (ORCID: https://orcid.org/0000-0001-9322-2558)
- Tomasz Masior
- Simon Lal (ORCID: https://orcid.org/0000-0002-6245-8864)
- Kishore Iyer (ORCID: https://orcid.org/0000-0002-1446-3271)
- Tim Vanuytsel (ORCID: https://orcid.org/0000-0001-8728-0903)
- Palle Bekker Jeppesen (ORCID: https://orcid.org/0000-0001-9680-6938)
- Nader N. Youssef (ORCID: https://orcid.org/0009-0007-9537-6711)
Institutions
- Cleveland Clinic (US)
- Ironwood Pharmaceuticals (United States) (US)
- University of Utah (US)
- Hôpital Beaujon (FR)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- University of Manchester (GB)
- Mount Sinai Medical Center (US)
- KU Leuven (BE)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100083
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00